GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pharmicell Co Ltd (XKRX:005690) » Definitions » Cyclically Adjusted Revenue per Share

Pharmicell Co (XKRX:005690) Cyclically Adjusted Revenue per Share : ₩0.00 (As of Sep. 2024)


View and export this data going back to 1988. Start your Free Trial

What is Pharmicell Co Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Pharmicell Co's adjusted revenue per share for the three months ended in Sep. 2024 was . Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is ₩0.00 for the trailing ten years ended in Sep. 2024.

During the past 12 months, Pharmicell Co's average Cyclically Adjusted Revenue Growth Rate was -100.00% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 10.10% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 8.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Pharmicell Co was 11.00% per year. The lowest was -3.70% per year. And the median was 5.80% per year.

As of today (2024-12-14), Pharmicell Co's current stock price is ₩7210.00. Pharmicell Co's Cyclically Adjusted Revenue per Share for the quarter that ended in Sep. 2024 was ₩0.00. Pharmicell Co's Cyclically Adjusted PS Ratio of today is .

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Pharmicell Co was 48.30. The lowest was 6.82. And the median was 17.96.


Pharmicell Co Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for Pharmicell Co's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pharmicell Co Cyclically Adjusted Revenue per Share Chart

Pharmicell Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 493.78 523.08 581.32 675.42 698.06

Pharmicell Co Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 688.27 698.06 700.90 - -

Competitive Comparison of Pharmicell Co's Cyclically Adjusted Revenue per Share

For the Biotechnology subindustry, Pharmicell Co's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pharmicell Co's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pharmicell Co's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Pharmicell Co's Cyclically Adjusted PS Ratio falls into.



Pharmicell Co Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Pharmicell Co's adjusted Revenue per Share data for the three months ended in Sep. 2024 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Sep. 2024 (Change)*Current CPI (Sep. 2024)
=245.279/*
=

Current CPI (Sep. 2024) = .

Pharmicell Co Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201412 113.894 99.098 0.000
201503 97.357 99.720 0.000
201506 103.409 100.050 0.000
201509 119.593 100.110 0.000
201512 134.029 100.220 0.000
201603 126.449 100.560 0.000
201606 110.403 100.790 0.000
201609 137.386 101.460 0.000
201612 110.459 101.560 0.000
201703 93.006 102.850 0.000
201706 120.097 102.610 0.000
201709 90.763 103.490 0.000
201712 128.957 102.990 0.000
201803 100.429 104.100 0.000
201806 84.481 104.130 0.000
201809 121.506 105.650 0.000
201812 164.996 104.350 0.000
201903 144.048 104.490 0.000
201906 147.453 104.880 0.000
201909 105.545 105.200 0.000
201912 177.229 105.120 0.000
202003 155.424 105.540 0.000
202006 191.365 104.870 0.000
202009 130.811 106.200 0.000
202012 146.670 105.765 0.000
202103 205.374 107.357 0.000
202106 227.989 107.579 0.000
202109 221.088 108.759 0.000
202112 211.472 109.676 0.000
202203 227.586 111.806 0.000
202206 195.426 114.083 0.000
202209 260.389 114.831 0.000
202212 315.228 115.200 0.000
202303 225.003 116.550 0.000
202306 308.310 117.140 0.000
202309 204.603 119.111 0.000
202312 227.172 118.848 0.000
202403 184.953 118.848 0.000
202406 296.025 0.000
202409 245.279 0.000

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


Pharmicell Co  (XKRX:005690) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Pharmicell Co was 48.30. The lowest was 6.82. And the median was 17.96.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Pharmicell Co Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of Pharmicell Co's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Pharmicell Co Business Description

Industry
Traded in Other Exchanges
N/A
Address
12F Chungho B/D, 3-2 Nonhyun-dong Gangnam-gu, Seoul, KOR, 135-010
Pharmicell Co Ltd is a biotechnology company, engages in the manufacturing of biopharmaceutical medicines in South Korea. Its biopharmaceutical business engages in the development and manufacture of stem cell therapeutic drugs and stem cell-based cosmetics and others. Its products under development include mesenchymal stem cell products, such as Cellgram_AMI, a heart disease drug; Cellgram_IS and Cellgram_SCI, which are brain/nerve disorder drugs; Cellgram_Lung, a pulmonary disease drug; Cellgram_LC, a liver disease drug; and Cellgram_ED and Cellgram_CLI for the treatment of graft-versus-host disease, kidney transplant, impotence, and critical lower limb ischemia.

Pharmicell Co Headlines

No Headlines